BD- DAPTO 350 INJ

About BD- DAPTO 350 INJ

Product Name: BD-DAPTO 350 Injection
Generic Name: Daptomycin for Injection
Strength: 350 mg
Brand: BDR
Dosage Form: Lyophilized Powder for Injection
Route of Administration: Intravenous (IV)
Packaging: Single vial

Product Description:

BD-DAPTO 350 Injection contains Daptomycin 350 mg, a cyclic lipopeptide antibiotic used for the treatment of serious bacterial infections caused by Gram-positive organisms. It is particularly effective against complicated skin and soft tissue infections, bacteremia, and right-sided infective endocarditis caused by susceptible strains.

Daptomycin works by disrupting bacterial cell membrane function, leading to rapid depolarization, inhibition of protein, DNA, and RNA synthesis, and bacterial cell death. It is administered intravenously under strict medical supervision in hospital settings.

Key Features:

Potent Gram-positive antibacterial activity

Effective against MRSA and other resistant strains

Rapid bactericidal action

Suitable for hospital and institutional use

Manufactured under high-quality pharmaceutical standards

Indications:

Complicated skin and skin structure infections (cSSSI)

Staphylococcus aureus bacteremia

Right-sided infective endocarditis

Other serious Gram-positive infections

Storage:

Store below 25C. Protect from light and moisture.

Manufacturer:

BDR Pharmaceuticals International Pvt. Ltd.

Supply:

Available for hospital, institutional, bulk, and export supply.

Powerful Antibiotic Action for Serious Infections

BD-DAPTO 350 Injection is specifically crafted to combat severe bacterial infections caused by Gram-positive organisms, including those from resistant strains like MRSA. Its broad spectrum and potent action make it indispensable in hospitals for conditions where prompt and effective intervention is necessary. The product is manufactured in alignment with international pharmaceutical standards.


Intravenous Delivery for Optimal Efficacy

Administered intravenously, BD-DAPTO 350 ensures rapid entry into the bloodstream, allowing for swift and targeted bacterial eradication. The lyophilized powder format ensures product stability and makes reconstitution easy in clinical environments. This method is strictly managed by healthcare professionals to maximize benefits and minimize risks.


Key Uses and Indications

BD-DAPTO 350 is indicated for treating complicated skin and skin structure infections, Staphylococcus aureus bacteremia, right-sided infective endocarditis, and other serious Gram-positive bacterial infections. Its efficacy against difficult-to-treat and resistant infections supports its role as a critical therapy in hospitals and other healthcare institutions.